These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

296 related items for PubMed ID: 30332571

  • 1. PD-1 Blockade-Induced Pruritus Treated with a Mu-Opioid Receptor Antagonist.
    Kwatra SG, Ständer S, Kang H.
    N Engl J Med; 2018 Oct 18; 379(16):1578-1579. PubMed ID: 30332571
    [No Abstract] [Full Text] [Related]

  • 2. Arterial thrombosis and anti-PD-1 blockade.
    Boutros C, Scoazec JY, Mateus C, Routier E, Roy S, Robert C.
    Eur J Cancer; 2018 Mar 18; 91():164-166. PubMed ID: 29289455
    [No Abstract] [Full Text] [Related]

  • 3. Diabetic ketoacidosis following immunotherapy for lung cancer.
    Skorpen PK, Margull J.
    Tidsskr Nor Laegeforen; 2019 Feb 26; 139(4):. PubMed ID: 30808100
    [No Abstract] [Full Text] [Related]

  • 4. Immune Checkpoint Inhibitor-Associated Central Adrenal Insufficiency.
    Mishra T, He G, Sreeram K, Rauf M, Subahi A, Hazem M.
    Am J Ther; 2019 Feb 26; 26(5):e626-e627. PubMed ID: 30277909
    [No Abstract] [Full Text] [Related]

  • 5. HTLV-1 seropositive patients with lung cancer treated with PD-1 inhibitors.
    Yoneshima Y, Kato K, Minami H, Ikeda M, Watanabe H, Yoshimoto G, Miyamoto T, Akashi K, Nakanishi Y, Okamoto I.
    Cancer Sci; 2020 Sep 26; 111(9):3395-3396. PubMed ID: 32557883
    [No Abstract] [Full Text] [Related]

  • 6. Gougerot-Sjogren-like syndrome under PD-1 inhibitor treatment.
    Teyssonneau D, Cousin S, Italiano A.
    Ann Oncol; 2017 Dec 01; 28(12):3108. PubMed ID: 29045656
    [No Abstract] [Full Text] [Related]

  • 7. Severe Oral Mucositis: A Rare Adverse Event of Pembrolizumab.
    Lederhandler MH, Ho A, Brinster N, Ho RS, Liebman TN, Lo Sicco K.
    J Drugs Dermatol; 2018 Jul 01; 17(7):807-809. PubMed ID: 30005106
    [Abstract] [Full Text] [Related]

  • 8. Toxicity profile of approved anti-PD-1 monoclonal antibodies in solid tumors: a systematic review and meta-analysis of randomized clinical trials.
    Costa R, Carneiro BA, Agulnik M, Rademaker AW, Pai SG, Villaflor VM, Cristofanilli M, Sosman JA, Giles FJ.
    Oncotarget; 2017 Jan 31; 8(5):8910-8920. PubMed ID: 27852042
    [Abstract] [Full Text] [Related]

  • 9. PD-1 Blockade-induced Inflammatory Arthritis.
    Nobashi T, Mittra E.
    Radiology; 2018 Dec 31; 289(3):616. PubMed ID: 30277446
    [No Abstract] [Full Text] [Related]

  • 10. Radiologic and autopsy findings in a case of fatal immune checkpoint inhibitor-associated pneumonitis.
    Shea M, Rangachari D, Hallowell RW, Hollie NI, Costa DB, VanderLaan PA.
    Cancer Treat Res Commun; 2018 Dec 31; 15():17-20. PubMed ID: 30207283
    [Abstract] [Full Text] [Related]

  • 11. Pembrolizumab for classical Hodgkin's lymphoma.
    Burki TK.
    Lancet Oncol; 2016 Aug 31; 17(8):e324. PubMed ID: 27397043
    [No Abstract] [Full Text] [Related]

  • 12. Autoimmune-Related Primary Hypoparathyroidism Possibly Induced by the Administration of Pembrolizumab: A Case Report.
    Umeguchi H, Takenoshita H, Inoue H, Kurihara Y, Sakaguchi C, Yano S, Hasuzawa N, Sakamoto S, Sakamoto R, Ashida K.
    J Oncol Pract; 2018 Jul 31; 14(7):449-451. PubMed ID: 29906213
    [No Abstract] [Full Text] [Related]

  • 13. Mitochondrial myopathy associated with anti-programmed cell death 1 therapy.
    Ibrahim T, Adam C, Routier E, Slama A, Robert C.
    Eur J Cancer; 2019 Mar 31; 110():71-73. PubMed ID: 30772655
    [No Abstract] [Full Text] [Related]

  • 14. Severe polyradiculoneuritis associated with the combination of ipilimumab and pembrolizumab in a lung cancer patient.
    Cho HS, Lee KY, Hu CJ, Chung CC.
    Neurol India; 2018 Mar 31; 66(2):509-511. PubMed ID: 29547174
    [No Abstract] [Full Text] [Related]

  • 15. Atrophic exocrine pancreatic insufficiency associated with anti-PD1 therapy.
    Hoadley A, Sandanayake N, Long GV.
    Ann Oncol; 2017 Feb 01; 28(2):434-435. PubMed ID: 27864215
    [No Abstract] [Full Text] [Related]

  • 16. Alemtuzumab for Immune-Related Myocarditis Due to PD-1 Therapy.
    Esfahani K, Buhlaiga N, Thébault P, Lapointe R, Johnson NA, Miller WH.
    N Engl J Med; 2019 Jun 13; 380(24):2375-2376. PubMed ID: 31189042
    [No Abstract] [Full Text] [Related]

  • 17. Focal immune-related pancreatitis occurring after treatment with programmed cell death 1 inhibitors: a distinct form of autoimmune pancreatitis?
    Capurso G, Archibugi L, Tessieri L, Petrone MC, Laghi A, Arcidiacono PG.
    Eur J Cancer; 2018 May 13; 95():123-126. PubMed ID: 29530539
    [No Abstract] [Full Text] [Related]

  • 18. Anti-PD-1 associated retroperitoneal fibrosis.
    Daoussis D, Kraniotis P, Kalofonou F, Kalofonos H.
    Rheumatology (Oxford); 2021 Sep 01; 60(9):e329-e330. PubMed ID: 33729466
    [No Abstract] [Full Text] [Related]

  • 19. Pembrolizumab-associated mucous membrane pemphigoid in a patient with Merkel cell carcinoma.
    Haug V, Behle V, Benoit S, Kneitz H, Schilling B, Goebeler M, Gesierich A.
    Br J Dermatol; 2018 Oct 01; 179(4):993-994. PubMed ID: 29758087
    [No Abstract] [Full Text] [Related]

  • 20. Psoriatic arthritis induced by anti-programmed death 1 antibody pembrolizumab.
    Hara T, Mikita N, Ikeda T, Inaba Y, Kunimoto K, Kaminaka C, Kanazawa N, Yamamoto Y, Jinnin M.
    J Dermatol; 2019 Dec 01; 46(12):e466-e467. PubMed ID: 31376178
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.